Screener
Nektar Therapeutics NKTR Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liabilities, current portion | 22,531 | 20,495 |
| Total current liabilities | 57,708 | 53,536 |
| Operating lease liabilities, less current portion | 60,631 | 65,256 |
| Liabilities related to the sales of future royalties, net | 60,270 | 63,157 |
| Other long-term liabilities | 8,446 | 8,625 |
| Total liabilities | 187,055 | 190,574 |
| Commitments and contingencies | ||
| Stockholders’ equity: |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's liability related to sale of potential future royalties non current net of issuance costs?
- Nektar Therapeutics (NKTR) reported liability related to sale of potential future royalties non current net of issuance costs of $60.27M in Q1 2026.
- How has Nektar Therapeutics's liability related to sale of potential future royalties non current net of issuance costs changed year-over-year?
- Nektar Therapeutics's liability related to sale of potential future royalties non current net of issuance costs decreased by 30.2% year-over-year, from $86.32M to $60.27M.
- What is the long-term trend for Nektar Therapeutics's liability related to sale of potential future royalties non current net of issuance costs?
- Over 5 years (2020 to 2025), Nektar Therapeutics's liability related to sale of potential future royalties non current net of issuance costs has grown at a -20.6% compound annual growth rate (CAGR), from $200.34M to $63.16M.
- What does liability related to sale of potential future royalties non current net of issuance costs mean?
- This represents the non-current portion of financial obligations arising from the monetization of future royalty streams associated with the company's drug portfolio. It reflects the present value of future payments owed to third-party investors who provided upfront capital in exchange for a share of future product revenues. This liability is adjusted over time as royalties are earned and paid, serving as a key indicator of the company's long-term debt-like commitments tied to its intellectual property assets.
Ask your AI about Nektar Therapeutics's liability related to sale of potential future royalties non current net of issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude